Skip to main content
. 2024 Mar 12;10(1):e003839. doi: 10.1136/rmdopen-2023-003839

Figure 5.

Figure 5

Disease response (DAS28-CRP or CDAI LDA) and VAS pain score of ≤20 or ≤10 mm in patients with disease response (at week 24) in (A) FINCH 1, (B) FINCH 2 and (C) FINCH 3. ADA, adalimumab; CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28-CRP, Disease Activity Score-28 with C-reactive protein; FIL100/200, filgotinib 100/200 mg; LDA, low disease activity; MTX, methotrexate; PBO, placebo; VAS, visual analogue scale.